See the DrugPatentWatch profile for Onivyde
Onivyde is classified as a chemotherapy drug [1]. It is a liposomal formulation of irinotecan, a topoisomerase I inhibitor, used in the treatment of pancreatic cancer [2].
What is Onivyde used for?
Onivyde is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma in combination with fluorouracil and leucovorin, following disease progression after prior gemcitabine-based chemotherapy [2].
How does Onivyde work?
Onivyde delivers irinotecan in a liposomal form, which is designed to prolong the drug's circulation time and alter its distribution. Irinotecan, once released from the liposomes, inhibits topoisomerase I, an enzyme essential for DNA replication and repair. This inhibition leads to DNA damage and cell death in cancer cells [2].
When does Onivyde's patent protection expire?
Information regarding specific patent expiry dates for Onivyde is typically found through specialized patent databases. For detailed patent information, including expiry timelines and any associated litigation, resources like DrugPatentWatch.com are valuable [3].
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde treatment include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and pyrexia [1]. Severe side effects can occur, and patients should discuss any concerns with their healthcare provider.